We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
-22.83%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.04B
AUM Growth
-$590M
Cap. Flow
-$271M
Cap. Flow %
-26.22%
Top 10 Hldgs %
52.21%
Holding
94
New
6
Increased
10
Reduced
22
Closed
23

Top Buys

Rank Stock Value
1
ARLZ
Aralez Pharmaceuticals Inc.
ARLZ
+$19.6M
2
NVDQ
Novadaq Technologies Inc.
NVDQ
+$18.9M
3
RPTP
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
+$18.4M
4
CSII
Cardiovascular Systems, Inc.
CSII
+$14.8M
5
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$7.38M

Top Sells

Rank Stock Value
1
BHC icon
Bausch Health
BHC
+$91.5M
2
NVRO
NEVRO CORP.
NVRO
+$31.5M
3
EBS icon
Emergent Biosolutions
EBS
+$26.9M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$22.9M
5
ATRC icon
AtriCure
ATRC
+$18M

Sector Composition

Rank Sector Weight
1 Healthcare 70.61%
2 Technology 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TLGT
26
DELISTED
Teligent, Inc
TLGT
$11.2M 1.08%
228,773
– –
IOVA icon
27
Iovance Biotherapeutics
IOVA
$2.28B
$10.7M 1.03%
2,105,519
– –
DVAX
28
DELISTED
Dynavax Technologies
DVAX
$10.5M 1.02%
547,810
-81,900
-13% -$1.66M
RDHL
29
Redhill Biopharma
RDHL
$3.91M
$10M 0.97%
818
-12
-1% -$126K
CPRX
30
DELISTED
Catalyst Pharmaceutical
CPRX
$9.59M 0.93%
8,200,000
+4,016,823
+96% +$6.23M
QLTI
31
DELISTED
QLT Inc
QLTI
$8.85M 0.85%
4,445,527
– –
ELGX
32
DELISTED
Endologix Inc
ELGX
$8.36M 0.81%
100,000
– –
ZGNX
33
DELISTED
Zogenix, Inc.
ZGNX
$8.15M 0.79%
882,312
-204,800
-19% -$2.05M
PRTK
34
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$8.04M 0.78%
530,282
-1
-0% -$15
DSCI
35
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$7.94M 0.77%
2,562,104
– –
ADMA icon
36
ADMA Biologics
ADMA
$1.92B
$7.8M 0.75%
964,193
– –
EGLT
37
DELISTED
Egalet Corporation
EGLT
$7.78M 0.75%
1,134,750
– –
SBBP
38
DELISTED
Strongbridge Biopharma plc.
SBBP
$7.55M 0.73%
1,656,705
– –
XNPT
39
DELISTED
XENOPORT, INC.
XNPT
$7.18M 0.69%
+1,592,067
New +$7.33M
AMRN
40
Amarin Corp
AMRN
$286M
$7.15M 0.69%
233,761
+25,000
+12% +$742K
CORI
41
DELISTED
Corium International, Inc.
CORI
$6.96M 0.67%
1,802,092
– –
TRVN
42
DELISTED
Trevena, Inc.
TRVN
$6.72M 0.65%
1,300
-300
-19% -$1.51M
PTX
43
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$6.39M 0.62%
609,083
– –
ELOS
44
DELISTED
Syneron Medical Ltd
ELOS
$6.36M 0.61%
870,013
-185,208
-18% -$1.33M
ACGN
45
DELISTED
Aceragen Inc
ACGN
$6.13M 0.59%
22,778
– –
ARCT icon
46
Arcturus Therapeutics
ARCT
$161M
$5.9M 0.57%
222,444
– –
ANAC
47
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$5.34M 0.52%
+100,000
New +$7.38M
VXRT
48
DELISTED
Vaxart
VXRT
$5.23M 0.51%
316,974
– –
PLXP
49
DELISTED
PLx Pharma Inc. Common Stock
PLXP
$4.43M 0.43%
58,247
– –
ZVRA icon
50
Zevra Therapeutics
ZVRA
$585M
$4.35M 0.42%
18,731
-27,040
-59% -$6.55M
1
2
3 4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q1 2016 Portfolio in Review

As of Q1 2016, Broadfin Capital held 94 positions worth $1.04B, down 36% from $1.63B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Broadfin Capital withdrew a net $271M in Q1 2016, closing 23 positions and reducing 22 holdings. Its most notable exit was Bausch Health, an estimated $91.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, down from 79% a quarter earlier, followed by Technology.

Against the trend, Broadfin Capital opened a new position in Aralez Pharmaceuticals Inc. worth $13.5M.

  • Broadfin Capital's largest Q1 2016 buy was Aralez Pharmaceuticals Inc.: 3,800,000 shares worth $13.5M.
  • Broadfin Capital added most to Novadaq Technologies Inc. in Q1 2016, an estimated $18.9M increase.
  • Broadfin Capital's biggest Q1 2016 reduction was NEVRO CORP., cutting an estimated $31.5M.
  • Broadfin Capital fully exited Bausch Health in Q1 2016, selling an estimated $91.5M.
  • Broadfin Capital's ten largest holdings make up 52% of its $1.04B portfolio in Q1 2016.
  • Broadfin Capital opened 6 new positions and closed 23 in Q1 2016.
  • Broadfin Capital's portfolio value fell 36% quarter-over-quarter to $1.04B.

Based on Broadfin Capital's 13F filing for Q1 2016, filed 16 May 2016.